What is Alzheon?
Alzheon, established in 2013 and headquartered in Massachusetts, is dedicated to advancing an oral, disease-modifying treatment for Alzheimer's disease. The company's lead candidate is currently in Phase 3 testing, representing a critical stage in its development pipeline. The company's focus on an oral anti-amyloid therapy positions it within a highly competitive and significant market, aiming to address a major unmet medical need.
How much funding has Alzheon raised?
Alzheon has raised a total of $182M across 9 funding rounds:
Private Equity
$7.3M
Series A
$10M
Debt
$6.9M
Debt
$1.3M
Private Equity
$15.8M
Debt
$150K
Series D
$40M
Series E
$100M
Private Equity (2014): $7.3M, investors not publicly disclosed
Series A (2015): $10M, investors not publicly disclosed
Debt (2015): $6.9M, investors not publicly disclosed
Debt (2016): $1.3M, investors not publicly disclosed
Private Equity (2017): $15.8M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Series D (2022): $40M, investors not publicly disclosed
Series E (2024): $100M featuring Alerce Medical Technology Partners
Key Investors in Alzheon
Alerce Medical Technology Partners
Alerce Medical Technology Partners is likely a venture capital firm or strategic investor focused on the medical technology sector, potentially specializing in late-stage pharmaceutical development or innovative healthcare solutions.
PPP
Public-Private Partnership
What's next for Alzheon?
With the recent major strategic investment and its enterprise-level funding history, Alzheon is poised to advance its Phase 3 clinical trials for its Alzheimer's disease treatment. The substantial capital infusion is expected to fuel the final stages of development, regulatory submissions, and potential commercialization efforts. This financing round signals strong investor confidence in Alzheon's therapeutic approach and its potential to impact the Alzheimer's market significantly.
See full Alzheon company page
